DDInter1853 DDInter1435
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Tretinoin {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Tretinoin {u} (Compound) binds {v} (Gene) CYP1A1
Tretinoin {u} (Compound) upregulates {v} (Gene) DHRS3
Tretinoin {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Tretinoin {u} (Compound) downregulates {v} (Gene) ATP6V1D
Tretinoin {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Tretinoin (Compound) resembles Isotretinoin (Compound)
Tretinoin (Compound) treats peripheral nervous system neoplasm (Disease)
Tretinoin (Compound) binds CYP1A1 (Gene)
Tretinoin (Compound) upregulates DHRS3 (Gene)
Tretinoin (Compound) is included by Retinoids (Pharmacologic Class)
Tretinoin (Compound) downregulates ATP6V1D (Gene)
Tretinoin (Compound) causes Agranulocytosis (Side Effect)